

APPROVED – CSU IBC Meeting Minutes

Meeting title	CSU IBC Meeting August 2025
Date	August 13, 2025
Convened at	12:02PM MST
Location	Microsoft Teams (Virtual Meeting)
Open or closed meeting (If closed, why?)	The meeting was closed briefly from 1:08pm to 1:15pm to discuss personal, proprietary, and/or security matters. The meeting was open the remainder of the time.
Review of prior meeting minutes	July 9, 2025, meeting minutes were approved with minor corrections
Adjournment	1:31PM MST
Recorded by	M. Ramey & C. Johnson

Attendees

Check if Attending (Members):	Check if Attending (Alternate Members):
<input checked="" type="checkbox"/> Jessica Ayers, Animal expert	<input type="checkbox"/> Lon Kendall, Director LAR
<input checked="" type="checkbox"/> Donald Bade, Unaffiliated	
<input type="checkbox"/> Angela Bosco-Lauth, Veterinary Virology	
<input checked="" type="checkbox"/> Chaoping Chen, Chair	
<input checked="" type="checkbox"/> Jason Cummings, lab representative	
<input type="checkbox"/> Dan Frazen, Unaffiliated	
<input type="checkbox"/> Jean Peccoud, Synthetic Biology	
<input type="checkbox"/> Brendan Podell, Mycobacteria specialist	
<input checked="" type="checkbox"/> Ann Powers, Virology	
<input checked="" type="checkbox"/> Robyn Roberts, Plant expert	
<input checked="" type="checkbox"/> Joanie Ryan, Assistant Biosafety Director	<input checked="" type="checkbox"/> Rebecca Moritz, Biosafety Office Director*
<input type="checkbox"/> Tony Schountz, Virology	<input checked="" type="checkbox"/> Christine Johnson, IBC/IRE Manager, Alternate-at-Large*
Quorum = 7 voting members; 7 in attendance	*non-voting at this meeting
Non-Voting Members:	
<input type="checkbox"/> James Graham, EHS Director	
<input checked="" type="checkbox"/> Joni Van Sickle, Occupational Health Coord.	
ORCC Staff (non-voting):	
<input checked="" type="checkbox"/> Michelle Ramey, Assistant Compliance Coord.	<input checked="" type="checkbox"/> Sonia Aleman Rivera, Assistant Biosafety Officer
<input type="checkbox"/> Nicole Marlenee, Biosecurity Specialist	<input type="checkbox"/> Kelly Kim, Assistant Biosafety Officer
<input type="checkbox"/> Scott Van Scotter, Biosafety Trainer	
Additional Guests:	
Linda Schutjer, OGC	

Quorum was maintained throughout. Any member with a conflict of interest left the meeting during discussion and/or committee determination on the conflicted items.

1. Agent/Project Review

a. PI name/Lab	Bowen Lab
Project Number and Title	25-0478: Efficacy of new Brucellosis vaccines in mice
Agents used	<ul style="list-style-type: none"> • <i>Brucella melitensis</i>
Project Overview	This project plans to evaluate a series of vaccines based on a recombinant Francisella platform to protect mice against <i>Brucella melitensis</i> challenge.
Planned Modifications	The vectors are made in a different lab by their collaborators; recombinant vectors will be tested in mice.
NIH Guidelines Section	III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL3/ABSL3
Discussion	<p>This is an experienced PI in BMS</p> <ol style="list-style-type: none"> 1. Request to update experience statement to reflect current duties
Verification of training	All lab members have completed the required training in SciShield.
Verification of facilities	The lab is up to date on lab inspections.
Motion	A motion was made to approve the project pending modifications described above (see Discussion).
Vote	The motion was unanimously approved.

b. PI name/Lab	Mehaffy Lab
Project Number and Title	25-048B: Whole genome sequencing of Staphylococcus and Coliform bacteria from the environment
Agents used	<ul style="list-style-type: none"> • Coliforms • <i>Staphylococcus spp</i>
Project Overview	This project is part of a Course-based Undergraduate Research Experience (CURE) (MIP270) in which students will isolate Staphylococci and Coliforms (lactose fermenting bacteria) from environmental samples, isolate bacteria colonies in selective media, and extract high molecular weight gDNA.
Planned Modifications	NA
NIH Guidelines Section	NA
Proposed containment conditions (BSL, ABSL, etc.)	BSL2
Discussion	<p>This is an experienced PI in MIP</p> <ol style="list-style-type: none"> 1. The lab space is due for a biosafety outreach visit. <p>For both agents:</p> <ol style="list-style-type: none"> 2. In the Agent Description, please add a statement indicating that the individual genus species cannot be provided due to the nature of the environmental sample source. 3. Under Methods of Inactivation, please add a chemical disinfectant, as well as the concentration and contact time.

	For the Coliforms AARF: 4. Some species of these genera can infect plants (e.g., Klebsiella), the IBC requests changing Pathogenic for plants to Y.
Verification of training	All lab members have completed the required training in SciShield.
Verification of facilities	The lab is due to schedule a Biosafety visit.
Motion	A motion was made to approve the agents and project pending modifications described above (see Discussion) and the Biosafety visit.
Vote	The motion was unanimously approved.

c. PI name/Lab	Schwerdtfeger Lab
Project Number and Title	25-051B: Human tissue and biofluid markers of neurodegenerative disease
Agents used	<ul style="list-style-type: none"> • <i>Salmonella enterica</i> • <i>Pseudomonas Aeruginosa</i> • <i>Epstein-Barr Virus (Human gammaherpesvirus-4)</i> • <i>Human cytomegalovirus (human herpesvirus-5)</i>
Project Overview	This project involves tissue collections taken during routine colonoscopy for evaluating tissue and stool proteins and metabolites that may serve as biomarkers of neurological disease status or predict progression.
Planned Modifications	NA
NIH Guidelines Section	NA
Proposed containment conditions (BSL, ABSL, etc.)	BSL2
Discussion	<p>This is a new PI in BMS</p> <ol style="list-style-type: none"> 1. The laboratory is due for Biosafety Visit. 2. The IBC requests clarification regarding the use of laminar flow hood, BL2 hood, and BSC hood. The IBC also recommends using something other than a laminar flow hood for dissection as laminar flow pushes the air across the surface toward the user, providing product protection only, no user or environmental protection. Clarify whether homogenization for pre-fixative ELISA occurs in a BSC. 3. Isolation of DNA or RNA proposed from serum which typically lacks cells, request clarification 4. Epstein-Barr Virus and Human cytomegalovirus are bloodborne pathogens. This question should be changed from No to Yes <p>For the 4 Pathogen Registration Forms</p> <ol style="list-style-type: none"> 5. For all bacteria and viruses listed, there are discrepancies in the decontamination processes. 1) Each one is listed as using a different disinfectant, which makes things more complicated in the lab. If possible, it is recommended to use

	1-2 disinfectants. 2) UV irradiation would not be appropriate for surfaces; they should be wiped down with disinfectant. Autoclaves cycles should be at least 121C for 30-60 minutes depending on the size and content of the load.
Verification of training	All lab members have completed the required training in SciShield.
Verification of facilities	The lab is due to schedule a Biosafety visit.
Motion	A motion was made to approve the Lab registration pending modifications described above (see Discussion)
Vote	The motion was unanimously approved.

d. PI name/Lab	Goodrich Lab
Project Number and Title	N/A
Agents used	<ul style="list-style-type: none"> • <i>Vibrio Cholerae</i> • <i>Shigella Flexneri</i> • <i>Enteropathogenic Escherichia coli (EPEC wild-type strain E2348/69)</i>
Project Overview	N/A
Planned Modifications	NA
NIH Guidelines Section	NA
Proposed containment conditions (BSL, ABSL, etc.)	BSL2
Discussion	<p>This is an experienced PI in MIP</p> <ol style="list-style-type: none"> 1. The laboratory is due for a Biosafety Outreach Visit. 2. For all 3 Pathogen Registration Forms, under "Describe use of PPE", please add that eye protection must be worn at all times in the lab. 3. Remind the Lab to submit a new Project before beginning work with the 3 new agents and to add the cell lines mentioned in the agent forms. <p>For Pathogen Registration Form - <i>Vibrio Cholerae</i>:</p> <ol style="list-style-type: none"> 4. In the last sentence under "Disposal", please specify that "sharps container" will be used for disposal of sharps. <p>For Pathogen Registration Form - <i>Shigella Flexneri</i>:</p> <ol style="list-style-type: none"> 5. Under the methods of decontamination, please add the actual concentration of sodium hypochlorite (i.e. 10%) used for disinfection instead of "¼ bleach per gallon." <p>For Pathogen Registration Form - <i>Enteropathogenic Escherichia coli (EPEC wild-type strain E2348/69)</i>:</p> <ol style="list-style-type: none"> 6. Under the methods of decontamination, please add the actual concentration of sodium hypochlorite (i.e. 10%) used for disinfection instead of "1:9 dilution of bleach in water."
Verification of training	There are a few overdue biosafety trainings; please address these at your earliest convenience.
Verification of facilities	The laboratory is due for a Biosafety Outreach Visit.

Motion	A motion was made to approve the new agents pending modifications described above (see Discussion)
Vote	The motion was unanimously approved.

e. PI name/Lab	Steffen Lab
Project Number and Title	25-052B: Collection and characterization of tick salivary components
Agents used	<ul style="list-style-type: none"> • <i>Powassan virus</i> • <i>Tick-borne encephalitis virus</i>
Project Overview	This project intends to study the role of tick salivary components and secreted flavivirus NS1 in modulating innate immune responses.
Planned Modifications	NA
NIH Guidelines Section	NA
Proposed containment conditions (BSL, ABSL, etc.)	BSL3
Discussion	<p>This is a relatively new PI in MIP, with previous approvals at BSL2.</p> <ol style="list-style-type: none"> 1. In the Description of Experimental details, please clarify that N95 or PAPRs will be worn at all times while in BSL3, not just when using non-ventilated cabinets. 2. In the Arthropod Survey, clarify that some infections occur at BSL-3. Additionally, the request the Lab consider doing the vortexing for submersion infections in the biosafety cabinet and using screw-cap tubes over Eppendorf tubes for this process. 3. In Microbial Agents Survey, should be modified to reflect that some of these agents are bloodborne pathogens and some TBEV are Select Agents (however not current strains working with). <p>For Pathogen Registration Form - Powassan virus (POWV):</p> <ol style="list-style-type: none"> 4. If possible, consider an alternative to using needles to reduce risks of accidental exposure to lab personnel 5. Specified locations are in the non-respiratory protection area of the lab space; clarify whether other users in the area will wear an N95 when work is occurring in the non-ventilated cabinet. <p>For Pathogen Registration Form - Tick-borne encephalitis virus (TBEV):</p> <ol style="list-style-type: none"> 6. Specified locations are in the non-respiratory protection area of the lab space; clarify whether other users in the area will wear an N95 when work is occurring in the non-ventilated cabinet. 7. Under "Strain Information", please specify that no TBEV of the select agent subtypes (Far Eastern and Siberian) will be acquired or used.

Verification of training	All lab members have completed the required training in SciShield.
Verification of facilities	The is up to date on lab inspections.
Motion	A motion was made to approve the agents and project pending modifications described above (see Discussion)
Vote	The motion was unanimously approved.

2. Amendments requiring full IBC review

a. PI name/Lab	Steffen Lab
Project Number and Title	24-059B: Flavivirus research
Agents used	<i>West Nile virus, Dengue virus, Yellow Fever virus, Langat virus, Usutu virus</i>
Project Overview	This project investigates the role of innate immunity in the control of flavivirus infection in the periphery and in the central nervous system (CNS) by exploring which cell types and molecular factors are essential for the control of the virus.
Amendment request	Amended to add Powassan virus and Tick-Borne Encephalitis virus and increase the biosafety level from 2 to 3
Planned Modifications	Expressing viral proteins from BSL3 viruses in E. coli
NIH Guidelines Section	III-D-2
Proposed containment conditions (BSL, ABSL, etc.)	BSL3
Discussion	This is a relatively new PI in MIP, with previous approvals at BSL2. The IBC requests clarification whether all of the agents on this project will be worked with at BSL3, or if some work is still done at BSL2. If work will be done at both BSL2 and BSL3, the Lab needs to specify the locations for each type of work, as well as differences in PPE and decontamination procedures.
Verification of training	All lab members are up to date on the required training.
Verification of facilities	The is up to date on lab inspections.
Motion	A motion was made to approve the amendment request pending modifications described above (see Discussion)
Vote	The motion was unanimously approved.

3. New Business – none

4. Unfinished Business

a. Business item	New IBC minutes requirements from NIH/update to minutes format
Discussion	The IBC Manager reminded the IBC that going forward, meeting minutes will be posted on CSU's IBC website. The committee reviewed the updated minutes template, along with the updated Meeting and Minutes SOP. The IBC will utilize the option to close the meeting to discuss sensitive topics that do not involve work subject to the NIH Guidelines. This is described in the SOP and includes personal, proprietary, and/or security issues. Since there was

	no meeting in June, the first minutes to be posted will be from the July meeting. They will be posted in August, after they have been approved by the committee and reviewed by OGC.
Action Item	This was an FYI, no vote or action item required.

5. Reports

a. Coordinator's Report	Next IBC meeting: Wednesday, September 10, 2025
b. Biosafety Office Report	<ol style="list-style-type: none"> 1. Inspections update: The RO has sent in the response for the recent Select Agent inspection. 2. Incident Reports: There were no incidents involving recombinant material during the past quarter.

6. Items to be read into the minutes

a. Items Reviewed at Previous IBC Meeting and Approved After Modification were completed	<p>Moreira Lab</p> <ol style="list-style-type: none"> 1. Pathogen Registration Forms <ol style="list-style-type: none"> a. Bacteria - Escherichia coli O157- and non-O157 Shiga toxin producing b. Bacteria - Listeria monocytogenes c. Bacteria - Salmonella spp. 2. Project: Food Safety Research - Moreira Lab (25-044B); BSL2. NIH Guidelines category non-exempt rDNA: NA
b. Items Reviewed and Approved by the Biosafety Officer or Chair since the last meeting	<ol style="list-style-type: none"> 1. Townsend Lab Project: <u>Nanofiber Patch with Gradient Presentation of Biomolecules for Treatment of Pediatric Tracheal Stenosis (25-020B)</u>; human samples, BSL2. NIH Guidelines category non-exempt rDNA: NA 2. Robertson Lab Project: <u>Evaluation of Otsuka priority regimens in mice (25-021B)</u>; BSL3/ABSL3. NIH Guidelines category non-exempt rDNA: NA 3. Tang Lab Project: <u>Walnut as a first food during complementary feeding on gut microbiota and immunity development in breastfed infants (25-025B)</u>; human samples, BSL2. NIH Guidelines category non-exempt rDNA: NA 4. Detamore Lab Project: <u>Enhancing Bone Regeneration for a Patient-Fitted Temporomandibular Joint Prosthesis (25-027B)</u>; human samples, BSL2. NIH Guidelines category non-exempt rDNA: NA 5. Thomson Lab Project: <u>Validation of Zynex Monitoring Solutions. Noninvasive COOximeter as Compared to Arterial Blood CO-Oximetry (25-029B)</u>; human sample, BSL2. NIH Guidelines category non-exempt rDNA: NA

	<p>6. Bark Lab</p> <ul style="list-style-type: none"> a. Project: <u>Effect of Turbulence on Hemostasis and Thrombosis (25-030B)</u>; human samples, BSL2. NIH Guidelines category non-exempt rDNA: NA b. Project: <u>Developing Diagnostic Devices to Assess Hemostasis and Thrombosis (25-031B)</u>; human samples, BSL2. NIH Guidelines category non-exempt rDNA: NA <p>7. Ebel Lab Project: <u>Verena Implementation – Mosquitoes (25-037B)</u>; BSL3. NIH Guidelines category non-exempt rDNA: NA</p> <p>8. Jarosova Lab</p> <ul style="list-style-type: none"> c. Project: <u>Behavioral and Neurochemical Measurements in Zebrafish (25-050B)</u>; BSL1. NIH Guidelines category non-exempt rDNA: NA d. Project: <u>Environmental Stressors and Neurodevelopment: A Zebrafish-Based Model System (25-049B)</u>; BSL1. NIH Guidelines category non-exempt rDNA: NA <p>9. Bowen Lab</p> <ul style="list-style-type: none"> e. Project: <u>Duck antiserum to Japanese encephalitis virus (25-034B)</u>; BSL3/ABSL3. NIH Guidelines category non-exempt rDNA: NA f. Project: <u>Pathogenesis of dengue virus infection in poultry (25-040B)</u>; BSL2/ABSL2. NIH Guidelines category non-exempt rDNA: NA g. Project: <u>Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure (25-046B)</u>; BSL3/ABSL3. NIH Guidelines category non-exempt rDNA: NA <p>10. Lappin Lab Project: <u>Use of light therapy for treatment of superficial pyoderma (25-038B)</u>; BSL1/ABSL1. NIH Guidelines category non-exempt rDNA: NA</p> <p>11. Leach Lab Project: <u>Characterization of Pantoea ananatis, a rice bacterial pathogen in the USA (25-032B)</u>; BSL1/BSL1 in rice. NIH Guidelines category non-exempt rDNA: NA</p> <p>12. LaRocca, Tom Project: <u>Analyses of non-coding RNAs in human brain samples (25-033B)</u>; human sample, BSL2; NIH Guidelines category non-exempt rDNA: NA</p> <p>13. Henao-Tamayo, Marcela Project: <u>Research Training Program in Metabolism, Obesity and Type 2 Diabetes (25-019B)</u>; BSL2/ABSL2. NIH Guidelines category non-exempt rDNA: NA</p>
--	---